The Illumina cancer testing spinout, which counts a range of other corporates as investors, is talking to advisers about a flotation this year.
Grail, an oncology diagnostics-focused spinout of US-based genomics technology provider Illumina, plans to float in Hong Kong, Bloomberg reported yesterday, citing people with knowledge of the matter.
The offering would take place this year and is working with advisers for an IPO that coud raise up to $500m, though a firm amount has not been decided, one source said.
Grail is working on a blood test that will be able to detect cancer relatively early, before symptoms are visible, in…
